Development and validation of a serum microRNA biomarker panel for detecting gastric cancer in a high-risk population

So, Jimmy Bok Yan; Kapoor, Ritika; Zhu, Feng; Koh, Calvin Jianyi; Zhou, Lihan; Zou, Ruiyang; Tang, Yew Chung; Goo, Patrick C.K.; Rha, Sun Young; Chung, Hyun Cheol; Yoong, Joanne; Yap, Celestial T.; Rao, Jaideepraj; Chia, Chung King; Tsao, Stephen; Shabbir, Asim; Lee, Jonathan Wei Jie; Lam, Kong Peng; Hartman, Mikael; Yong, Wei Peng; Too, Heng Phon; Yeoh, Khay Guan

doi:10.1136/gutjnl-2020-322065

Cited by 117 publications

(90 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…So et al recently developed a clinical assay for the detection of gastric cancer based on a 12-miRNA Biomarker panel with AUCs of 0.93 and 0.92 in the discovery and verification cohorts, respectively. Although the sample size in the training set was smaller and AUC was lower in their study than in our study, the 12-miR assay was validated and cost-effectiveness was analyzed in a large prospective validation cohort consisting of 5282 participants [27].…”

Section: Discussionmentioning

confidence: 67%

“…A variety of serum or plasma miRNAs are frequently upregulated or downregulated in gastric cancer [24]. Although several groups have investigated the use of serum miRNAs to detect gastric cancer and predict the recurrence and prognosis of the disease [25][26][27]. To our knowledge, our current study is the largest cohort analysis of the use of serum miRNAs to detect EGC with the highest sensitivity and specificity reported to date.…”

Section: Discussionmentioning

confidence: 92%

See 1 more Smart Citation

A novel combination of serum microRNAs for the detection of early gastric cancer

Abe

Matsuzaki²,

Sudo³

et al. 2021

Gastric Cancer

View full text Add to dashboard Cite

Background The aim of this study was to identify serum miRNAs that discriminate early gastric cancer (EGC) samples from non-cancer controls using a large cohort. Methods This retrospective case–control study included 1417 serum samples from patients with EGC (seen at the National Cancer Center Hospital in Tokyo between 2008 and 2012) and 1417 age- and gender-matched non-cancer controls. The samples were randomly assigned to discovery and validation sets and the miRNA expression profiles of whole serum samples were comprehensively evaluated using a highly sensitive DNA chip (3D-Gene®) designed to detect 2565 miRNA sequences. Diagnostic models were constructed using the levels of several miRNAs in the discovery set, and the diagnostic performance of the model was evaluated in the validation set. Results The discovery set consisted of 708 samples from EGC patients and 709 samples from non-cancer controls, and the validation set consisted of 709 samples from EGC patients and 708 samples from non-cancer controls. The diagnostic EGC index was constructed using four miRNAs (miR-4257, miR-6785-5p, miR-187-5p, and miR-5739). In the discovery set, a receiver operating characteristic curve analysis of the EGC index revealed that the area under the curve (AUC) was 0.996 with a sensitivity of 0.983 and a specificity of 0.977. In the validation set, the AUC for the EGC index was 0.998 with a sensitivity of 0.996 and a specificity of 0.953. Conclusions A novel combination of four serum miRNAs could be a useful non-invasive diagnostic biomarker to detect EGC with high accuracy. A multicenter prospective study is ongoing to confirm the present observations.

show abstract

Section: Discussionmentioning

confidence: 67%

Section: Discussionmentioning

confidence: 92%

A novel combination of serum microRNAs for the detection of early gastric cancer

Abe

Matsuzaki²,

Sudo³

et al. 2021

Gastric Cancer

View full text Add to dashboard Cite

show abstract

“…However, these studies have not been validated in independent cohorts. miR-103, miR-126, miR-93, miR-29, miR-424, and miR-181 are among AD-associated miRNAs with biomarker potential whose application as disease biomarkers has been validated in other disorders (So et al, 2020).…”

Section: Discussionmentioning

confidence: 99%

The Eminent Role of microRNAs in the Pathogenesis of Alzheimer's Disease

Samadian

Gholipour

Hajiesmaeili

et al. 2021

Front. Aging Neurosci.

View full text Add to dashboard Cite

Alzheimer's disease (AD) is an irrevocable neurodegenerative condition characterized by the presence of senile plaques comprising amassed β-amyloid peptides (Aβ) and neurofibrillary tangles mainly comprising extremely phosphorylated Tau proteins. Recent studies have emphasized the role of microRNAs (miRNAs) in the development of AD. A number of miRNAs, namely, miR-200a-3p, miR-195, miR-338-5p, miR-34a-5p, miR-125b-5p, miR-132, miR-384, miR-339-5p, miR-135b, miR-425-5p, and miR-339-5p, have been shown to participate in the development of AD through interacting with BACE1. Other miRNAs might affect the inflammatory responses in the course of AD. Aberrant expression of several miRNAs in the plasma samples of AD subjects has been shown to have the aptitude for differentiation of AD subjects from healthy subjects. Finally, a number of AD-modifying agents affect miRNA profile in cell cultures or animal models. We have performed a comprehensive search and summarized the obtained data about the function of miRNAs in AD in the current review article.

show abstract

“…Furthermore, besides their therapeutic potential, circulating miRNAs represent the clinically valuable group of biomarkers. Recently, the very first clinically validated diagnostic kit has started to be used for the non-invasive diagnostics/screening of gastric cancer using levels of 12 plasmatic miRNAs 90 . In the cardiovascular field, the discovery of clinically reliable markers still needs to solve numerous technological challenges; especially, there is the need to unify both the preanalytical (e.g., samples collection, extracellular fluid selection, storage, and handling) and the analytical (microarray analysis and next-generation sequencing standardization, the unification of internal or spike-in control use to normalize obtained qRT-PCR data) processes.…”

Section: Discussionmentioning

confidence: 99%

MicroRNAs as theranostic markers in cardiac allograft transplantation: from murine models to clinical practice

et al. 2021

View full text Add to dashboard Cite

Congestive heart failure affects about 23 million people worldwide, and cardiac allograft transplantation remains one of the last options for patients with terminal refractory heart failure. Besides the infectious or oncological complications, the prognosis of patients after heart transplantation is affected by acute cellular or antibody-mediated rejection and allograft vasculopathy development. Current monitoring of both conditions requires the performance of invasive procedures (endomyocardial biopsy sampling and coronary angiography or optical coherence tomography, respectively) that are costly, time-demanding, and non-comfortable for the patient. Within this narrative review, we focus on the potential pathophysiological and clinical roles of microRNAs (miRNAs, miRs) in the field of cardiac allograft transplantation. Firstly, we provide a general introduction about the status of cardiac allograft function monitoring and the discovery of miRNAs as post-transcriptional regulators of gene expression and clinically relevant biomarkers found in the extracellular fluid. After this general introduction, information from animal and human studies are summarized to underline the importance of miRNAs both in the pathophysiology of the rejection process, the possibility of its modulation by altering miRNAs levels, and last but not least, about the use of miRNAs in the clinical practice to diagnose or predict the rejection occurrence.

show abstract

Development and validation of a serum microRNA biomarker panel for detecting gastric cancer in a high-risk population

Cited by 117 publications

References 31 publications

A novel combination of serum microRNAs for the detection of early gastric cancer

A novel combination of serum microRNAs for the detection of early gastric cancer

The Eminent Role of microRNAs in the Pathogenesis of Alzheimer's Disease

MicroRNAs as theranostic markers in cardiac allograft transplantation: from murine models to clinical practice

Contact Info

Product

Resources

About